Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Meningitis

ClinicalTrials.gov lists 441 trials for Meningitis or a narrower condition beneath it. Sanofi Pasteur, a Sanofi Company has the most among industry and government lead sponsors, with 48.

MeSH D008581 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 26 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 71 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 103 Phase 4 Phase 4 42 Not applicable Not applicable 65 Observational Observational 110 Phase 1 Phase 1 26 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 71 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 103 Phase 4 Phase 4 42 Not applicable Not applicable 65 Observational Observational 110

Trials per phase

1 more section with rows

257 of the 441 trials are tagged with Meningitis itself; the rest are tagged with a narrower condition beneath it.

Get the Meningitis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Meningitis trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 24

1993: 1 trials (Observational 1) 1997: 1 trials (Phase 2 1) 2000: 1 trials (Phase 2 1) 2001: 5 trials (Observational 2, Phase 4 1, Phase 2 1, Phase 1 1) 2002: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 2003: 7 trials (Observational 1, Phase 4 3, Phase 2 3) 2004: 7 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 3) 2005: 15 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 2 7, Phase 1 2) 2006: 22 trials (Observational 3, Not applicable 2, Phase 4 2, Phase 3 8, Phase 2 5, Phase 1 2) 2007: 12 trials (Phase 3 8, Phase 2 1, Phase 1/2 2, Phase 1 1) 2008: 15 trials (Observational 2, Not applicable 1, Phase 3 7, Phase 2 3, Phase 1/2 1, Phase 1 1) 2009: 13 trials (Observational 2, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 5, Phase 1 1) 2010: 21 trials (Observational 6, Not applicable 1, Phase 4 3, Phase 3 4, Phase 2/3 1, Phase 2 5, Phase 1/2 1) 2011: 22 trials (Observational 5, Not applicable 1, Phase 4 3, Phase 3 8, Phase 2 4, Phase 1 1) 2012: 23 trials (Observational 2, Not applicable 2, Phase 4 5, Phase 3 8, Phase 2/3 2, Phase 2 1, Phase 1/2 1, Phase 1 2) 2013: 18 trials (Observational 3, Not applicable 2, Phase 4 2, Phase 3 7, Phase 2 3, Phase 1/2 1) 2014: 17 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2015: 24 trials (Observational 9, Not applicable 5, Phase 4 3, Phase 3 3, Phase 2 1, Phase 1 3) 2016: 19 trials (Observational 4, Not applicable 2, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2017: 15 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1/2 1) 2018: 22 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 6, Phase 1 3) 2019: 20 trials (Observational 8, Not applicable 5, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2020: 19 trials (Observational 10, Not applicable 2, Phase 4 2, Phase 3 5) 2021: 21 trials (Observational 9, Not applicable 4, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1 1) 2022: 11 trials (Observational 6, Not applicable 4, Phase 3 1) 2023: 13 trials (Observational 3, Not applicable 2, Phase 4 3, Phase 3 2, Phase 2 2, Phase 1 1) 2024: 15 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1/2 1, Phase 1 1) 2025: 13 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2/3 2, Phase 2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 22
2025 13
2024 15
2023 13
2022 11
2021 21
2020 19
2019 20
2018 22
2017 15

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 25 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 26 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 288 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Meningitis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 26
Phase 1/2 11
Phase 2 71
Phase 2/3 12
Phase 3 103
Phase 4 42
Not applicable 65
Observational 110
Expanded access 1

How many Meningitis trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 15
Recruiting 37
Enrolling by invitation 3
Active, not recruiting 9
Completed 297

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Meningitis trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Sanofi Pasteur, a Sanofi Company 48
Novartis Vaccines 35
GlaxoSmithKline 22
Pfizer 22
National Institute of Allergy and Infectious Diseases (NIAID) 11

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Meningitis? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
AMPHOTERICIN B 18
Flucytosine 11

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Fluconazol 26
MenACWY CRM 11
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate 10
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 9
Meningococcal ACWY Conjugate Vaccine 6

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Meningitis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Gastroenteritis 182 29
Bronchiolitis 179 22
Pneumonia 151 36
Anemia 110 2
Bronchitis 99 13

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Meningitis? (108)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Experiences, challenges, gaps, and strategies for counselling persons presenting with advanced HIV-associated meningitis in Uganda. AIDS research and therapy 2025 Yes
Clinical utility of the FilmArray® meningitis/encephalitis panel in children with suspected central nervous system infection in a low-resource setting - a prospective study in Southwestern Uganda. BMC infectious diseases 2025 Yes
Clinical features, etiologies, and outcomes of central nervous system infections in intensive care: A multicentric retrospective study in a large Brazilian metropolitan area. Journal of critical care 2024 Yes
Priorities for hearing loss prevention and estimates of global cause-specific burdens of hearing loss: a systematic rapid review. The Lancet. Global health 2024 Yes
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia. The New England journal of medicine 2023 Yes

Showing 5 of 108 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages